Should I buy or sell Aridis Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDS shares. View ARDS analyst ratings or view top-rated stocks .

What is Aridis Pharmaceuticals' stock price target for 2024?

1 analysts have issued twelve-month target prices for Aridis Pharmaceuticals' shares. Their ARDS share price targets range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next year. This suggests a possible upside of 3,150.7% from the stock's current price. View analysts price targets for ARDS or view top-rated stocks among Wall Street analysts .

How have ARDS shares performed in 2024?

Aridis Pharmaceuticals' stock was trading at $0.0701 on January 1st, 2024. Since then, ARDS stock has decreased by 12.2% and is now trading at $0.0615. View the best growth stocks for 2024 here .

When is Aridis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ARDS earnings forecast .

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $1.43. The company earned $0.52 million during the quarter.

What other stocks do shareholders of Aridis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO) , VBI Vaccines (VBIV) , Cidara Therapeutics (CDTX) , Dynavax Technologies (DVAX) , Inovio Pharmaceuticals (INO) , Matinas BioPharma (MTNB) , Gilead Sciences (GILD) , Ocular Therapeutix (OCUL) , Pluristem Therapeutics (PSTI) and SCYNEXIS (SCYX) .

When did Aridis Pharmaceuticals IPO?

Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ARDS

Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free ARDS Stock Alerts

$0.06

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.06
▼
$0.06
50-Day Range: $0.06
▼
$0.08
52-Week Range: $0.05
▼
$0.54

Volume: 407,922 shs
Average Volume: 103,013 shs
Market Capitalization: $2.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Get Aridis Pharmaceuticals alerts:

Aridis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 3,150.7% Upside
$2.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $0.07 to ($0.09) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.41 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Aridis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aridis Pharmaceuticals has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ARDS.

0.0

Dividend Strength

Dividend Yield
Aridis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Aridis Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARDS.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for ARDS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aridis Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Aridis Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 9.65% of the stock of Aridis Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aridis Pharmaceuticals are expected to decrease in the coming year, from $0.07 to ($0.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aridis Pharmaceuticals is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aridis Pharmaceuticals is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Aridis Pharmaceuticals Stock (NASDAQ:ARDS)

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

ARDS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARDS Stock News Headlines

March 14, 2024 | uk.investing.com

Aridis Pharmaceuticals Inc (ARDS)

February 10, 2024 | bbc.co.uk

Irish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protest

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

December 15, 2023 | finance.yahoo.com

Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024

November 3, 2023 | markets.businessinsider.com

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

November 3, 2023 | finance.yahoo.com

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

November 1, 2023 | morningstar.com

Aridis Pharmaceuticals Inc ARDS

October 22, 2023 | benzinga.com

Aridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, Predictions

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

October 21, 2023 | msn.com

HC Wainwright & Co. Maintains Aridis Pharmaceuticals (ARDS) Buy Recommendation

October 20, 2023 | markets.businessinsider.com

FDA’s Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals’ Investment Appeal: An Analyst’s Buy Recommendation

September 15, 2023 | finance.yahoo.com

ARDS Sep 2023 2.500 call

September 15, 2023 | finance.yahoo.com

Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

August 21, 2023 | investing.com

Aridis Pharma (ARDS) Earnings Dates & Reports

August 2, 2023 | finance.yahoo.com

Aridis Pharmaceuticals Announces $2 Million Offering

July 18, 2023 | finance.yahoo.com

Why Are Aridis Pharmaceuticals Shares Moving Higher Today?

July 17, 2023 | finance.yahoo.com

Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301

July 13, 2023 | finance.yahoo.com

Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301

July 12, 2023 | finance.yahoo.com

Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation

June 22, 2023 | marketwatch.com

Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

June 20, 2023 | finance.yahoo.com

Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

June 9, 2023 | finanznachrichten.de

Aridis Pharmaceuticals, Inc.: Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

June 8, 2023 | finance.yahoo.com

Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

June 1, 2023 | benzinga.com

Aridis Pharmaceuticals Stock (NASDAQ:ARDS), Guidance and Forecast

May 31, 2023 | finance.yahoo.com

Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

May 25, 2023 | finance.yahoo.com

Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q

April 26, 2023 | finance.yahoo.com

Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K

See More Headlines

Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ARDS
CUSIP: N/A
CIK: 1614067
Web: www.aridispharma.com
Phone: (408) 385-1742
Fax: 408-960-3822
Employees: 37
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.00
High Stock Price Target: $2.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +3,150.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 0.88
P/E Growth: N/A
Net Income: $-30,370,000.00
Net Margins: -5.11%
Pretax Margin: -5.11%
Return on Equity: N/A
Return on Assets: -20.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.24
Quick Ratio: 0.24

Sales & Book Value

Annual Sales: $3.09 million
Price / Sales: 0.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.16) per share
Price / Book: -0.05

Miscellaneous

Outstanding Shares: 47,930,000
Free Float: 45,293,000
Market Cap: $2.95 million
Optionable: Not Optionable
Beta: 1.00

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Eric J. Patzer Ph.D. (Age 75)
Founder & Executive Chairman
Comp: $240k
Dr. Vu L. Truong Ph.D. (Age 60)
Founder, CEO, Chief Scientific Officer & Director
Comp: $631.65k
Dr. Hasan Jafri M.D. (Age 57)
Chief Medical Officer
Comp: $559.36k
Ms. Tamara S. Allen (Age 57)
Vice President of Finance
Mr. Jeffrey J. Fessler Esq. (Age 61)
J.D., Acting General Counsel

Key Competitors

View All Competitors

ARDS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aridis Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDS shares.
View ARDS analyst ratings or view top-rated stocks.
What is Aridis Pharmaceuticals' stock price target for 2024?: 1 analysts have issued twelve-month target prices for Aridis Pharmaceuticals' shares. Their ARDS share price targets range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next year. This suggests a possible upside of 3,150.7% from the stock's current price.
View analysts price targets for ARDS or view top-rated stocks among Wall Street analysts.
How have ARDS shares performed in 2024?: Aridis Pharmaceuticals' stock was trading at $0.0701 on January 1st, 2024. Since then, ARDS stock has decreased by 12.2% and is now trading at $0.0615.
View the best growth stocks for 2024 here.
When is Aridis Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ARDS earnings forecast.

How were Aridis Pharmaceuticals' earnings last quarter?: Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $1.43. The company earned $0.52 million during the quarter.
What other stocks do shareholders of Aridis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Pluristem Therapeutics (PSTI) and SCYNEXIS (SCYX).
When did Aridis Pharmaceuticals IPO?: Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.
How do I buy shares of Aridis Pharmaceuticals?: Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARDS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis

Aridis Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About Aridis Pharmaceuticals Stock (NASDAQ:ARDS)

ARDS Stock Price History

ARDS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ARDS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™